Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Interleukin-6 - Sonnet Biotherapeutics Holdings

X
Drug Profile

Recombinant Interleukin-6 - Sonnet Biotherapeutics Holdings

Alternative Names: atexakin alfa; r-IL-6; recombinant IL-6; SON 080; SON-081

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer RELIEF THERAPEUTICS Holding; Sonnet BioTherapeutics Holdings, Inc; Xequel Bio
  • Class Interleukins
  • Mechanism of Action Interleukin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Peripheral nerve injuries
  • Phase I Diabetic neuropathies

Most Recent Events

  • 12 Apr 2024 Sonnet BioTherapeutics terminates a phase I/II trial in Peripheral nerve injuries in Australia (SC), due to lack of enrolment (NCT05435742)
  • 17 Jan 2024 Phase-I development in Diabetic-neuropathies is ongoing in Switzerland and USA (Parenteral) (Sonnet BioTherapeutics Holdings pipeline, January 2024)
  • 17 Jan 2024 Phase-I development in Peripheral-nerve-injuries is ongoing in Switzerland and USA (Parenteral) (Sonnet BioTherapeutics Holdings pipeline, January 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top